Management of Osteoporosis Medication after Osteoporotic Fracture
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The aim of this study was to provide helpful information for use in selection of an appropriate medication after osteoporotic fractures through conduct of a literature review. In addition, a review of the recommendations of several societies for prevention of subsequent fractures was performed and the appropriate choice of medication for treatment of atypical femur fractures was examined. Clinical perspective was obtained and an updated search of literature was conducted across PubMed and MEDLINE and relevant articles were selected. The articles were selected manually according to relevance, and the references for identified articles and reviews were also evaluated for relevance. The following areas are reviewed: Commonly prescribed osteoporosis medications: BPs (bisphosphonates), denosumab, and SERMs (selective estrogen receptor modulators) in antiresorptive medications and recombinant human parathyroid hormone teriparatide, recently approved Romosuzumab in anabolic agents, clinical practice guidelines for the management of osteoporosis, osteoporotic fracture, and atypical femur fracture. Most medications for treatment of osteoporosis do not delay fracture healing and the positive effect of teriparatide on fracture healing has been confirmed. In cases where an osteoporotic fracture is diagnosed, risk assessment should be performed for selection of very high-risk patients in order to prevent subsequent fractures, and administration of anabolic agents is recommended.
Abstract
The aim of this study was to provide helpful information for use in selection of an appropriate medication after osteoporotic fractures through conduct of a literature review. In addition, a review of the recommendations of several societies for prevention of subsequent fractures was performed and the appropriate choice of medication for treatment of atypical femur fractures was examined. Clinical perspective was obtained and an updated search of literature was conducted across PubMed and MEDLINE and relevant articles were selected. The articles were selected manually according to relevance, and the references for identified articles and reviews were also evaluated for relevance. The following areas are reviewed: Commonly prescribed osteoporosis medications: BPs (bisphosphonates), denosumab, and SERMs (selective estrogen receptor modulators) in antiresorptive medications and recombinant human parathyroid hormone teriparatide, recently approved Romosuzumab in anabolic agents, clinical practice guidelines for the management of osteoporosis, osteoporotic fracture, and atypical femur fracture. Most medications for treatment of osteoporosis do not delay fracture healing and the positive effect of teriparatide on fracture healing has been confirmed. In cases where an osteoporotic fracture is diagnosed, risk assessment should be performed for selection of very high-risk patients in order to prevent subsequent fractures, and administration of anabolic agents is recommended.
참고문헌 (51)
- "Life expectancy" (2013)[URL]
- Cooper C, "Hip fractures in the elderly : a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)[DOI]
- Klotzbuecher CM, "Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis", J Bone Miner Res, 15, pp.721~739 (2000)[DOI]
- van Geel TA, "Clinical subsequent fractures cluster in time after first fractures", Ann Rheum Dis, 68, pp.99~102 (2009)[DOI]
- Smith DP, "Trauma in the elderly : determinants of outcome", South Med J, 83, pp.171~177 (1990)[DOI]
- von Rüden C, "Failure of fracture fixation in osteoporotic bone", Injury, 2, pp.S3~S10 (2016)[DOI]
- Cheung WH, "Fracture healing in osteoporotic bone", Injury, 2, pp.S21~S26 (2016)[DOI]
- Xue D, "Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials", J Orthop Surg Res, 9, pp.45~ (2014)[DOI]
- Colón-Emeric C, "Association between timing of zoledronic acid infusion and hip fracture healing", Osteoporos Int, 22, pp.2329~2336 (2011)[DOI]
- Duckworth AD, "Effect of alendronic acid on fracture healing : a multicenter randomized placebo-controlled trial", J Bone Miner Res, 34, pp.1025~1032 (2019)[DOI]
- Cecilia D, "Effect of alendronate in elderly patients after low trauma hip fracture repair", Osteoporos Int, 20, pp.903~910 (2009)[DOI]
- Rozental TD, "Comparison of radiographic fracture healing in the distal radius for patients on and offbisphosphonate therapy", J Hand Surg Am, 34, pp.595~602 (2009)[DOI]
- Ha KY, "Does bisphosphonatebased anti-osteoporosis medication affect osteoporotic spinal fracture healing?", Osteoporos Int, 27, pp.483~488 (2016)[DOI]
- Peter B, "Calcium phosphate drug delivery system : influence of local zoledronate release on bone implant osteointegration", Bone, 36, pp.52~60 (2005)[DOI]
- Aspenberg P, "Bisphosphonates and implants : an overview", Acta Orthop, 80, pp.119~123 (2009)[DOI]
- Tägil M, "Enhanced Pin fixation for un-coated standard pins by a single bisphosphonate infusion in hemicallotasis osteotomy. A double-blinded placebo controlled randomized study", Bone, 42(Suppl 1), pp.S87~S88 (2008)[DOI]
- Friedl G, "The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial", J Bone Joint Surg Am, 91, pp.274~281 (2009)[DOI]
- Dhert WJ, "Integration of press-fit implants in cortical bone : a study on interface kinetics", J Biomed Mater Res, 41, pp.574~583 (1998)[DOI]
- Ganz R, "Mechanical induction of bone resorption", Fortschr Kiefer Gesichtschir, 19, pp.45~48 (1975)
- Goldhahn J, "Implications for fracture healing of current and new osteoporosis treatments : an ESCEO consensus paper", Calcif Tissue Int, 90, pp.343~353 (2012)[DOI]
- Gerstenfeld LC, "Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing", J Bone Miner Res, 24, pp.196~208 (2009)[DOI]
- Adami S, "Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis : results from the FREEDOM trial", J Bone Miner Res, 25(Suppl 1), pp.MO0405~ (2010)[DOI]
- Cao Y, "Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats", J Bone Miner Res, 17, pp.2237~2246 (2002)[DOI]
- Spiro AS, "The SERM raloxifene improves diaphyseal fracture healing in mice", J Bone Miner Metab, 31, pp.629~636 (2013)[DOI]
- Andreassen TT, "Intermittent parathyroid hormone(1-34)treatment increases callus formation and mechanical strength of healing rat fractures", J Bone Miner Res, 14, pp.960~968 (1999)[DOI]
- Shibamoto A, "Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration", Int J Oral Sci, 10, pp.6~ (2018)[DOI]
- Aspenberg P, "Teriparatide for acceleration of fracture repair in humans : a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures", J Bone Miner Res, 25, pp.404~414 (2010)[DOI]
- Peichl P, "Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women", J Bone Joint Surg Am, 93, pp.1583~1587 (2011)[DOI]
- Huang TW, "Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures", Medicine(Baltimore), 95, pp.e3626~ (2016)[DOI]
- Li X, "Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis", J Bone Miner Res, 24, pp.578~588 (2009)[DOI]
- Agholme F, "Sclerostin antibody treatment enhances metaphyseal bone healing in rats", J Bone Miner Res, 25, pp.2412~2418 (2010)[DOI]
- Schemitsch EH, "Placebo-controlled study of romosozumab for the treatment of hip fractures", J Bone Joint Surg Am, 102, pp.693~702 (2020)[DOI]
- Bhandari M, "Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture : a randomized phase-2 study", J Bone Joint Surg Am, 102, pp.1416~1426 (2020)[DOI]
- Kim TY, "Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?", J Bone Joint Surg Br, 94, pp.956~960 (2012)[DOI]
- Amanat N, "Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair", J Bone Miner Res, 22, pp.867~876 (2007)[DOI]
- Hagino H, "A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture : primary results of the Japanese Osteoporosis Intervention Trial-5", Osteoporos Int, 32, pp.2301~2311 (2021)[DOI]
- Kanis JA, "European guidance for the diagnosis and management of osteoporosis in postmenopausal women", Osteoporos Int, 19, pp.399~428 (2008)[DOI]
- Kanis JA, "European guidance for the diagnosis and management of osteoporosis in postmenopausal women", Osteoporos Int, 30, pp.3~44 (2019)[DOI]
- Kanis JA, "Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures", Osteoporos Int, 31, pp.1~12 (2020)[DOI]
- Altintas¸ F, "The effect of risedronate treatment on bone turnover markers in patients with hip fracture", Acta Orthop Traumatol Turc, 41, pp.132~135 (2007)
- Lyles KW, "Zoledronic acid and clinical fractures and mortality after hip fracture", N Engl J Med, 357, pp.1799~1809 (2007)[DOI]
- 김광균, "The Effect of Teriparatide on the Hip: A Literature Review", Hip and Pelvis, 33(2), pp.45~52 (2021), 대한고관절학회
- Kim SJ, "Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures", Injury, 50, pp.1364~1370 (2019)[DOI]
- Shoback D, "Pharmacological management of osteoporosis in postmenopausal women : an endocrine society guideline update", J Clin Endocrinol Metab, 105, pp.dgaa048~ (2020)[DOI]
- Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update, 2020, pp.26(Suppl 1), 1~46
- Miyakoshi N, "Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis : a comparison between treatment with and without teriparatide", J Bone Miner Metab, 33, pp.553~559 (2015)[DOI]
- Saleh A, "Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures", HSS J, 8, pp.103~110 (2012)[DOI]
- Shi Z, "Effectiveness of teriparatide on fracture healing : a systematic review and meta-analysis", PLoS One, 11, pp.e0168691~ (2016)[DOI]
- van de Laarschot DM, "Medical management of patients after atypical femur fractures : a systematic review and recommendations from the European Calcified Tissue Society", J Clin Endocrinol Metab, 105, pp.1682~1699 (2020)[DOI]
- Lamy O, "Stopping denosumab", Curr Osteoporos Rep, 17, pp.8~15 (2019)[DOI]
- Anastasilakis AD, "Denosumab discontinuation and the rebound phenomenon : a narrative review", J Clin Med, 10, pp.152~ (2021)[DOI]
